doi: 10.1021/bi049957v.
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41
Affiliations
- PMID: 15209519
- DOI: 10.1021/bi049957v
Item in Clipboard
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41
Biochemistry.
.
Abstract
Peptides derived from the N- (N-HR) and C- (C-HR) terminal heptad repeat regions adjacent to the fusion peptide and transmembrane domains, respectively, of human immunodeficiency virus (HIV)-1 gp41 inhibit HIV-1 viral envelope glycoproteins (Env)-mediated cell fusion specifically. The mechanism of HIV-1 Env-mediated cell fusion and its inhibition by agents that target the N- and C-HR regions was investigated. Priming experiments with Env-expressing cells indicate that the N-HR region but not the C-HR region is exposed by treatment with sCD4 at 31 degrees C, whereas both the N- and C-HR regions are exposed at 37 degrees C.
Similar articles
-
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.J Mol Biol. 2004 Jun 25;340(1):9-14. doi: 10.1016/j.jmb.2004.04.027. J Mol Biol. 2004. PMID: 15184018
-
Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.Biochemistry. 2003 Dec 9;42(48):14150-8. doi: 10.1021/bi035154g. Biochemistry. 2003. PMID: 14640682
-
Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.J Med Chem. 2005 Apr 21;48(8):3036-44. doi: 10.1021/jm049026h. J Med Chem. 2005. PMID: 15828842
-
HIV-1 gp41: mediator of fusion and target for inhibition.AIDS Rev. 2003 Oct-Dec;5(4):214-21. AIDS Rev. 2003. PMID: 15012000 Review.
-
HIV fusion inhibitors.Rev Med Virol. 2010 Jan;20(1):23-33. doi: 10.1002/rmv.631. Rev Med Virol. 2010. PMID: 19827030 Review.
Cited by
-
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.Retrovirology. 2008 Dec 10;5:111. doi: 10.1186/1742-4690-5-111. Retrovirology. 2008. PMID: 19077194 Free PMC article. Review.
-
A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies.Int J Mol Sci. 2023 Jun 5;24(11):9779. doi: 10.3390/ijms24119779. Int J Mol Sci. 2023. PMID: 37298729 Free PMC article.
-
Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.J Mol Biol. 2006 Dec 1;364(3):283-9. doi: 10.1016/j.jmb.2006.09.017. Epub 2006 Sep 12. J Mol Biol. 2006. PMID: 17010381 Free PMC article.
-
The late endosome-resident lipid bis(monoacylglycero)phosphate is a cofactor for Lassa virus fusion.PLoS Pathog. 2021 Sep 7;17(9):e1009488. doi: 10.1371/journal.ppat.1009488. eCollection 2021 Sep. PLoS Pathog. 2021. PMID: 34492091 Free PMC article.
-
Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.J Virol. 2016 Dec 16;91(1):e01445-16. doi: 10.1128/JVI.01445-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795416 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
